Renuka R. Nair

Renuka R. Nair

Auto-generated profile, based on publicly available information

Renuka R. Nair

Division of Cellular and Molecular Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, 695011, India.

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2011 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SPSreeja Purushothaman
Sreeja Purushothaman
RNR. Renuka Nair
R. Renuka Nair
VHV. S. Harikrishnan
V. S. Harikrishnan
AFA. C. Fernandez
A. C. Fernandez

19 February 2008 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
AKAdiga Indira K.
Adiga Indira K.
NRNair Renuka R.
Nair Renuka R.

11 October 2018 in Hypertension Research
Verified
Journal Article
Closed access
PDF file
APAjay Godwin Potnuri
Ajay Godwin Potnuri
LALingesh Allakonda
Lingesh Allakonda
AAArulvelan Appavoo
Arulvelan Appavoo
SSSherin Saheera
Sherin Saheera
RNRenuka R. Nair
Renuka R. Nair

12 August 2016 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
PDF file
ISIsmael Saifudeen
Ismael Saifudeen
LSLakshmi Subhadra
Lakshmi Subhadra
RKRemani Konnottil
Remani Konnottil
RNR. Renuka Nair
R. Renuka Nair

1 September 2011 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
SPSreeja Purushothaman
Sreeja Purushothaman
MSMb Mohamed Sathik
Mb Mohamed Sathik
RNR Renuka Nair
R Renuka Nair
Prevention of left ventricular hypertrophy remains a challenge in the prevention of hypertension-induced adverse cardiac remodeling. Cardiac hypertrophy is associated with a shift in energy metabolism from predominantly fatty acid to glucose with a corresponding reduction in the expression of fatty acid oxidation enzyme genes. Although initially adaptive, the metabolic switch seems to be detrimental in the long run. This study was taken up with the objective of examining whether the stimulation of fatty acid oxidation by the activation of peroxisome proliferator-activated receptor alpha (PPARα), a key regulator of fatty acid metabolism, can prevent cardiac hypertrophy. Fenofibrate was used as the PPARα agonist. Spontaneously hypertensive rats (SHRs) in the initial stages of hypertrophy (2 months) and those with established hypertrophy (6 months) were treated with fenofibrate (100 mg·kg−1·d−1 for 60 days). Cluster of differentiation 36 (CD36)—responsible for myocardial fatty acid uptake, carnitine palmitoyl transferase 1β—a mitochondrial transporter protein and medium chain acyl-Co-A dehydrogenase—a key enzyme in beta oxidation of fatty acids were selected as indicators of fatty acid metabolism. Hypertrophy was apparent at 2 months and metabolic shift at 4 months of age in SHRs. The treatment prevented cardiac remodeling in young animals but aggravated hypertrophy in older animals. Hypertrophy showed a positive association with malondialdehyde levels and cardiac NF-κB gene expression, signifying the role of oxidative stress in the mediation of hypertrophy. Expression of carnitine palmitoyl transferase 1β and medium chain acyl-Co-A dehydrogenase was upregulated on treatment. However, CD36 showed an age-dependent variation on treatment, with no change in expression in young rats and downregulation in older animals. It is inferred that the stimulation of PPARα before the initiation of metabolic remodeling may prevent cardiac hypertrophy, but reactivation after the metabolic adaptation aggravates hypertrophy. Whether the downregulation of CD36 is mediated by decreased substrate availability remains to be explored. Age-dependent paradoxical effect on the heart in response to fenofibrate, used as a lipid-lowering drug, can have therapeutic implications.

11 August 2016 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SPSreeja Purushothaman
Sreeja Purushothaman
RNR. Renuka Nair
R. Renuka Nair